Company Profile

Ocata Therapeutics Inc (AKA: Advanced Cell Technology Inc)
Profile last edited on: 4/12/2018      CAGE: 47JU8      UEI: ESVKNNJNQZ83

Business Identifier: Regenerative ophthalmology therapeutics
Year Founded
First Award
Latest Award
Program Status
Inactive (Acquired)
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

33 Locke Drive
Marlborough, MA 01752
   (508) 756-1212
Location: Multiple
Congr. District: 03
County: Middlesex

Public Profile

On November 10, 2015 it was announced that Ocata had been acquired by Astellas Pharma for $379M. Previously known as Advanced Cell Technology Inc, In November the firm was renamed Ocata Therapeutics, Inc with change of its trading info to NASDAQ:OCAT. Ocata is a clinical stage biotechnology company, working in the regenerative ophthalmology therapeutics space. Various clinical trials are underway for treating Stargardt?s macular degeneration, dry age-related macular degeneration, and myopic macular degeneration, as well as pre-clinical trials for the treatment of other ocular disorders; and has pre-clinical stage assets in disease areas outside the field of ophthalmology, including autoimmune, inflammatory, and wound healing-related disorders. The firm's intellectual property portfolio includes pluripotent stem cell platforms, such as human embryonic stem cell and induced pluripotent stem cell platforms. The intellectual property portfolio also comprises cell therapy research programs, such as ophthalmology programs, which include macular degeneration, photoreceptor progenitor, retinal ganglion cell progenitor, and corneal endothelial programs; and other programs, such as mesenchymal stem cell, neuroprotective biological, and platelet programs.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Publicly Traded
Stock Info
IP Holdings

Awards Distribution by Agency

Key People / Management

  William M Caldwell IV -- Chairman and CEO

  Paul K Wotton -- President and CEO

  Jonathan F Atzen -- Senior Vice President and General Counsel

  Jose B Cibelli

  Pedro Huertas -- Chief Development Officer

  Robert P Lanza -- Chief Scientific Officer

  David Larocca

  Stephen Price -- Interim Sr. VP of Corp. Devel

  Matthew Vincent -- Director of Business Development

  Michael West -- Former President and Chief Scientific Officer

  Ivan Wolkind -- Vice President of Finance and Chief Accounting Officer